Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of APG-2575 alone or with anticancer therapy in advanced ER-positive breast cancer or solid tumors
CTR20212804Phase 2Active
- Sponsor
- Suzhou Yasheng Pharmaceutical
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisaftoclax in breast cancer, Nonhematologic neoplasms, sponsored by Suzhou Yasheng Pharmaceutical. Started Jan 2022; status: active.
02
Drugs
lisaftoclax
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20212804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212804.